Vicriviroc (malate)

CAT: 0804-HY-B0155B-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0155B-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM, , respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer[1][2].
CAS Number
[541503-81-5]
Product Name Alternative
SCH 417690 (malate) ; SCH-D (malate) ; MK-7690
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
CCR; HIV
Type
Reference compound
Related Pathways
Anti-infection; GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/vicriviroc-malate.html
Smiles
COC[C@@H](C1=CC=C(C=C1)C(F)(F)F)N2[C@H](CN(C3(CCN(CC3)C(C4=C(C)N=CN=C4C)=O)C)CC2)C.O=C(O)C(O)CC(O)=O
Molecular Formula
C32H44F3N5O7
Molecular Weight
667.72
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Strizki JM, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49 (12) :4911-4919.|[2]Bessudo A, et al. Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clin Colorectal Cancer. 2024;23 (3) :285-294.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3

Popular Products